Mangrove Partners Protagonist Therapeutics, Inc Transaction History
Mangrove Partners
- $769 Million
- Q3 2024
A detailed history of Mangrove Partners transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Mangrove Partners holds 439,314 shares of PTGX stock, worth $16.6 Million. This represents 2.57% of its overall portfolio holdings.
Number of Shares
439,314
Previous 439,314
-0.0%
Holding current value
$16.6 Million
Previous $15.2 Million
29.69%
% of portfolio
2.57%
Previous 1.71%
Shares
3 transactions
Others Institutions Holding PTGX
# of Institutions
243Shares Held
56.7MCall Options Held
71.7KPut Options Held
114K-
Farallon Capital Management LLC San Francisco, CA5.86MShares$222 Million1.32% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$218 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$205 Million3.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$159 Million0.0% of portfolio
-
State Street Corp Boston, MA3.18MShares$120 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $1.86B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...